Ferrioxamine as a magnetic resonance contrast agent. Preclinical studies and phase I and II human clinical trials

The preclinical and clinical trial experience with ferrioxamine (S-FDF; Salutar, Inc.) as a contrast agent for magnetic resonance imaging (MRI) is summarized. The results in 44 patients or subjects show that the drug is safe and well tolerated when given intravenously. In certain conditions, early r...

Full description

Saved in:
Bibliographic Details
Published inInvestigative radiology Vol. 23 Suppl 1; p. S281
Main Authors Worah, D, Berger, A E, Burnett, K R, Cockrill, H H, Kanal, E, Kendall, C, Leese, P T, Lyons, K P, Ross, E, Wolf, G L
Format Journal Article
LanguageEnglish
Published United States 01.09.1988
Subjects
Adult
Animals
Contrast Media
Deferoxamine
Dogs
Drug Evaluation
Drug Evaluation, Preclinical
Ferric Compounds
Gadolinium DTPA
Humans
Iron Chelating Agents
Magnetic Resonance Imaging
Male
Mice
Multicenter Studies as Topic
Organometallic Compounds
Pentetic Acid
Online AccessGet more information

Cover

More Information
Summary:The preclinical and clinical trial experience with ferrioxamine (S-FDF; Salutar, Inc.) as a contrast agent for magnetic resonance imaging (MRI) is summarized. The results in 44 patients or subjects show that the drug is safe and well tolerated when given intravenously. In certain conditions, early results show that the use of this contrast agent provides more information than can be obtained with MRI alone.
ISSN:0020-9996
DOI:10.1097/00004424-198809001-00061